Table 2.
Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
---|---|---|---|---|---|---|---|
Control | 300 ± 99 | 308 ± 104 | 373 ± 85 | 390 ± 94 | 390 ± 94 | 390 ± 94 | 403 ± 82 |
20 pm iNO | 393 ± 157 | 473* ± 43 | 479* ± 37 | 482* ± 23 | 485* ± 24 | 487* ± 18 | 488* ± 17 |
40 ppm iNO | 376 ± 85 | 398 ± 70 | 430 ± 54 | 454 ± 40 | 471 ± 36 | 463 ± 43 | 467 ± 45 |
Neurological deficit score on all days following cardiac arrest and cardiopulmonary resuscitation. Control animals exhibited severe neurological dysfunction. Inhaled nitric oxide (iNO)-treated animals had better neurological outcomes, with a statistically significant difference in animals treated with 20 ppm iNO on postoperative days 2–7; *p <0.05 for 20 ppm iNO vs. control; mean ± SD. Day 1: Control, n = 5; 20 ppm iNO, n = 10; 40 ppm iNO, n = 6. Days 2–7: Control, n = 4; 20 ppm iNO, n = 10; 40 ppm iNO, n = 6